Institutional members access full text with Ovid®

Share this article on:

Prolonged Survival With Continuous Infusion Topotecan: A Report of 2 Cases

Klopfenstein, Kathryn J. MD*; Scott, Suzanne RN, MS, CPNP; Schuller, David E. MD; Ruymann, Frederick B. MD

Journal of Pediatric Hematology/Oncology: June 2008 - Volume 30 - Issue 6 - p 468-470
doi: 10.1097/MPH.0b013e318169167b
Clinical and Laboratory Observations

Two patients with solid tumors were treated with 21-day continuous infusion topotecan as palliation therapy. Case 1: A 10-year-old girl was diagnosed with progressive, metastatic hepatocellular carcinoma. Twenty-one–day continuous infusion topotecan was started and she has had a partial response. Case 2: A 17-year-old girl developed a malignant fibrous histiocytoma as a second malignant neoplasm. After partial resection and failure of multiagent chemotherapy, she started continuous infusion topotecan and was disease-free for 58 months when she died of pneumonia. These cases suggest that topotecan given as 21-day continuous infusion is efficacious for palliation care.

*Department of Pediatrics, East Tennesse State University, Johnson City, TN

Division of Hematology/Oncology, Columbus Children's Hospital

Division of Surgical Oncology, The Arthur G. James Cancer Hospital, The Ohio State University, Columbus, OH

Reprints: Kathryn J. Klopfenstein, MD, Department of Pediatrics, East Tennesse State University, PO BOX 70578, Johnson City, TN 37601 (e-mail:

Received for publication October 2, 2006; accepted January 14, 2008

© 2008 Lippincott Williams & Wilkins, Inc.